Wealth Enhancement Advisory Services’s Amneal Pharmaceuticals AMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$385K Buy
60,365
+1,242
+2% +$22.4K ﹤0.01% 3091
2026
Q2
$316K Buy
59,123
+804
+1% +$11K ﹤0.01% 3158
2026
Q1
$223K Buy
58,319
+41,872
+255% +$562K ﹤0.01% 3052
2025
Q4
$225K Sell
16,447
-1,127
-6% -$12.9K ﹤0.01% 3177
2025
Q3
$182K Buy
17,574
+4,204
+31% +$37.7K ﹤0.01% 3171
2025
Q2
$113K Buy
+13,370
New +$101K ﹤0.01% 3121

Other funds holding AMRX

Wealth Enhancement Advisory Services's AMRX Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Amneal Pharmaceuticals (AMRX) stake by 2.1% in Q3 2026, buying an estimated $22.4K and bringing the position to 60,365 shares worth $385K. The position accounts for ﹤0.01% of the portfolio, ranked #3091.

Wealth Enhancement Advisory Services first reported a position in AMRX in Q2 2025 and has held it in 6 quarters since. 332 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

  • Wealth Enhancement Advisory Services held 60,365 shares of Amneal Pharmaceuticals worth $385K as of Q3 2026.
  • Wealth Enhancement Advisory Services bought 1,242 Amneal Pharmaceuticals shares in Q3 2026, an estimated $22.4K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3091 holding.
  • Wealth Enhancement Advisory Services first reported a position in Amneal Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • 332 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.